Can-Fite BioPharma Ltd. has found that cannabis compound induces the inhibition of liver cancer cell growth and the discovery is now being patented, according to BusinessWire.

  • The biotechnology firm said its pre-clinical studies demonstrated that a CBD rich cannabis fraction inhibited the growth of liver HEP-3b hepatocellular carcinoma cells via the A3AR.
  • The company has filed patent applications protecting its discovery of cannabinoid-based therapies. It already earlier developed drugs to treat liver diseases such as advanced liver cancer with its Namodenoson scheduled for a Phase III study in the fourth quarter.
  • Can-Fite CEO Dr. Pnina Fishman said the findings present a therapeutic opportunity for derived compounds in liver cancer, and that cannabinoid-based compounds can offer a safe and effective alternative for such unmet needs.
  • The medical cannabis market is projected to grow at a CAGR of 29% to $56.7 billion by 2026.